Meeting
2023 ASCO Annual Meeting
Introduction of E-Score: A gene expression score to characterize immunogenic versus oncogenic HPV expression in HNSCC.
Authors
Bailey Fabiny Garb
University of Michigan, Ann Arbor, MI
Bailey Fabiny Garb , Shiting Li , Christopher Carpenter , Chamila D. Perera , Steven B. Chinn , Nisha J. D'Silva , Laura S. Rozek , Maureen A. Sartor
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 6057)
DOI
10.1200/JCO.2023.41.16_suppl.6057
Abstract #
6057
Poster Bd #
49
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Association between human papillomavirus (HPV) status and duration of response of anti-programmed cell death protein-1 (PD-1) inhibitors in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
First Author: Kedar Kirtane
Poster
2023 ASCO Annual Meeting
Abemaciclib in recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC) harboring CDKN2A loss, and/or CCND1 and/or CDK6 amplification: A phase II multicenter trial.
First Author: Jerome Fayette
Poster
2022 ASCO Annual Meeting
PDS0101, a novel type I interferon and CD8 T-cell activating immunotherapy, in combination with pembrolizumab in subjects with recurrent/metastatic HPV16-positive head and neck squamous cell carcinoma (HNSCC).
First Author: Jared Weiss
Poster
2022 ASCO Annual Meeting
Recommended phase 2 dose (RP2D) of HB-200 arenavirus-based cancer immunotherapies in patients with HPV16+ cancers.
First Author: Siqing Fu